Cell.ai provides AI drug discovery and peptide design services using Tahoe-x1 and BoltzGen models. From data to molecule, pricing to patent licensing, we empower biotech innovation with transparent costs and collaborative partnerships.
🔬 Introduction
At Cell.ai, we specialize in AI drug discovery and peptide design using next-generation foundation models such as Tahoe-x1 and BoltzGen.
Our platform integrates large-scale biological data, generative AI, and predictive modeling to accelerate the discovery of novel therapeutic molecules.
By combining computational biology and AI-powered design, we enable biotech companies and research teams to shorten the development cycle while improving the accuracy of peptide and drug candidate generation.
⚙️ From Data to Molecule
Our AI-Bio Design Engine provides a seamless pipeline from data processing to molecule creation:
- Encode complex omics and cell-state data into model-ready representations.
- Generate peptides or small molecules targeting specific pathways.
- Conduct in-silico screening for binding affinity, ADMET profiles, and stability.
- Support experimental design and validation planning.
Learn more about our Cell.ai Research Platform to explore how we unify data and AI in life sciences.
💡 IP & Patent Licensing in AI Drug Discovery
Cell.ai transforms AI-generated molecules into patentable assets ready for commercialization.
We provide end-to-end IP and licensing services including:
- Patent drafting and novelty analysis.
- IP landscape mapping and competitor white-space identification.
- Global licensing negotiation and co-development agreements.
Through strategic partnerships, we help clients secure strong intellectual property positions in the competitive biotech landscape.
For further reading, see Nature Biotechnology on emerging trends in generative biology and drug design.
💰 Pricing for AI Drug Discovery and Peptide Design Services
Our pricing model is designed to scale with your research and development goals:
| Service Tier | Description | Typical Fee Range |
|---|---|---|
| Starter Screening | AI virtual screening for up to 100 candidate peptides or compounds | USD 5,000–15,000 per project |
| Advanced Molecular Design | Custom generative modeling using proprietary datasets and fine-tuned AI models | USD 25,000–80,000 per project |
| End-to-End Discovery Partnership | Full discovery + IP filing + licensing agreement | Revenue sharing / Equity / Licensing-based |
| Patent & Licensing Advisory | Patent drafting, novelty checks, IP strategy mapping | USD 3,000–10,000 per case |
We also offer SaaS access to our AI molecular design engine:
- Standard Plan: USD 2,000 / month
- Enterprise Plan (with API and priority compute): USD 5,000 / month
📩 Contact us for a detailed quotation or enterprise plan: info@cell.ai
🌍 Collaboration Opportunities
We partner with:
- Biotech & Pharma Companies: Integrate our AI-bio platform into your R&D workflow.
- Research Institutes: Explore peptide therapeutics and biomarker discovery.
- Investors & Accelerators: Gain exposure to frontier AI-biotech innovation.
Our flexible collaboration model supports both contract-based R&D and royalty-linked partnerships for AI drug discovery and peptide design projects.
🚀 Partner With Us
Join us at the frontier of AI-powered molecular innovation.
Let’s co-develop the next generation of therapeutics—faster, smarter, and with stronger IP protection.
📩 Reach our partnership team at info@cell.ai